Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 621

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1B
Chunk 621
---
 Following such approval by the Company’s stockholders, the Company has subsequently
amended the Charter to extend the date by which the Company must consummate a business combination to November 14, 2024. In connection
with the May Special Meeting, 1,581,733 shares of common stock of the Company were tendered for redemption at a redemption price
of approximately $10.78 per share for an aggregate redemption amount of $17,045,763, leaving $20,327,120 in the Trust Account
immediately after the redemptions and a tax withdrawal by the Company of $218,857. Additionally, the Company deposited an extension payment
of $50,000 into the Trust Account on each of May 14, 2024, June 13, 2024, July 12, 2024, August 13, 2024, September 10,
2024, and October 11, 2024.

F-9

OSR HOLDINGS, INC.

(f/k/a Bellevue Life Sciences Acquisition Corp.) 

NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024

November 2024 Special Meeting

On November
12, 2024, the Company held an annual meeting of its stockholders (the “November Special Meeting”). At the November Special
Meeting, the Company’s stockholders approved two proposals to amend the Company’s Charter. The stockholders approved a proposal
to amend the Charter to allow the Company to extend the date by which the Company must consummate a business combination from November
14, 2024 to February 14, 2025. The stockholders also approved a proposal to amend the Charter to remove the net tangible asset requirement
in order to expand the methods that the Company may employ so as not to become subject to the “penny stock” rules of the SEC.
The amendment was filed with the Delaware Secretary of State and has an effective date of November 12, 2024. The stockholders also duly
elected each of the five (5) existing directors to the Company’s Board of Directors until the next annual meeting of stockholders
following this annual meeting or until each such director’s successor is elected and qualified, subject to his earlier death, resignation
or removal. In connection with the November Special Meeting, 1,721,469 shares of common stock of the Company were tendered
for redemption at a redemption price of